Gene dose-dependent association of interleukin-1A [-889] allele 2 polymorphism with Alzheimer's disease

被引:45
作者
Combarros, O [1 ]
Sánchez-Guerra, M
Infante, J
Llorca, J
Berciano, J
机构
[1] Univ Cantabria, Hosp Marques de Valdecilla, Neurol Serv, Santander 39008, Spain
[2] Univ Cantabria, Sch Med, Div Prevent Med, E-39005 Santander, Spain
关键词
interleukin-1A; Alzheimer's disease; apolipoprotein E; polymorphism;
D O I
10.1007/s00415-002-0819-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Interleukin (IL)-1 is a potent proinflammatory cytokine that is markedly overexpressed in the brains of patients with Alzheimer's disease (AD). The ILIA [-889] allele 2 has been shown to increase AD risk, probably by upregulating the inflammatory cascade in the disease process. A case-control study utilizing a clinically well-defined group of 298 sporadic AD patients and 306 control subjects was performed to test this association. Our data show that the IL-1A allele 2 is a risk factor in a dose-dependent manner, the risk of developing AD with two copies of the IL-1A allele 2 (odds ratio 3.1, 95% Cl 1.30-7.45) being approximately double that of one copy of the IL-1A allele 2 (odds ratio 1.4, 95% CI 0.99-1.94, P for trend = 0.0004). Furthermore, the risk associated with the IL-1A allele 2 was not restricted to AD patients of a particular age, and we could confirm this association in our early-onset and late-onset AD patients.
引用
收藏
页码:1242 / 1245
页数:4
相关论文
共 22 条
  • [1] Inflammation and Alzheimer's disease
    Akiyama, H
    Barger, S
    Barnum, S
    Bradt, B
    Bauer, J
    Cole, GM
    Cooper, NR
    Eikelenboom, P
    Emmerling, M
    Fiebich, BL
    Finch, CE
    Frautschy, S
    Griffin, WST
    Hampel, H
    Hull, M
    Landreth, G
    Lue, LF
    Mrak, R
    Mackenzie, IR
    McGeer, PL
    O'Banion, MK
    Pachter, J
    Pasinetti, G
    Plata-Salaman, C
    Rogers, J
    Rydel, R
    Shen, Y
    Streit, W
    Strohmeyer, R
    Tooyoma, I
    Van Muiswinkel, FL
    Veerhuis, R
    Walker, D
    Webster, S
    Wegrzyniak, B
    Wenk, G
    Wyss-Coray, T
    [J]. NEUROBIOLOGY OF AGING, 2000, 21 (03) : 383 - 421
  • [2] Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists - The Cache County Study
    Anthony, JC
    Breitner, JCS
    Zandi, PP
    Meyer, MR
    Jurasova, I
    Norton, MC
    Stone, SV
    [J]. NEUROLOGY, 2000, 54 (11) : 2066 - 2071
  • [3] Association of an interleukin 1α polymorphism with Alzheimer's disease
    Du, Y
    Dodel, RC
    Eastwood, BJ
    Bales, KR
    Gao, F
    Lohmüller, F
    Müller, U
    Kurz, A
    Zimmer, R
    Evans, RM
    Hake, A
    Gasser, T
    Oertel, WH
    Griffin, WST
    Paul, SM
    Farlow, MR
    [J]. NEUROLOGY, 2000, 55 (04) : 480 - 483
  • [4] The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk
    Griffin, WST
    Nicoll, JAR
    Grimaldi, LME
    Sheng, JG
    Mrak, RE
    [J]. EXPERIMENTAL GERONTOLOGY, 2000, 35 (04) : 481 - 487
  • [5] Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO
  • [6] 2-N
  • [7] Lack of association of the interleukin-1α gene polymorphism with Alzheimer's disease in a Korean population
    Ki, CS
    Na, DL
    Kim, DK
    Kim, HJ
    Kim, JW
    [J]. ANNALS OF NEUROLOGY, 2001, 49 (06) : 817 - 818
  • [8] Gene polymorphisms of interleukin-1α influence the course of Alzheimer's disease
    Kölsch, H
    Ptok, U
    Bagli, M
    Papassotiropoulos, A
    Schmitz, S
    Barkow, K
    Kockler, M
    Rao, ML
    Maier, W
    Heun, R
    [J]. ANNALS OF NEUROLOGY, 2001, 49 (06) : 818 - 819
  • [9] Licastro F, 2000, ANN NEUROL, V48, P388, DOI 10.1002/1531-8249(200009)48:3<388::AID-ANA16>3.3.CO
  • [10] 2-7